NEOS Therapeutics

122 articles about NEOS Therapeutics

• Aytu BioScience Announces Close of Merger with Neos Therapeutics

  3/22/2021

  Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced the closing of its merger with Neos Therapeutics.

• Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

  3/12/2021

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that leading independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended Neos Therapeutics stockholders vote “FOR” the pending merger with Aytu BioScience,

• Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

  3/10/2021

  The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time

• Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

  2/10/2021

  Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc.

• Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

  1/4/2021

  Neos Therapeutics, Inc., a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.

• Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

  12/10/2020

  Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

• Neos Therapeutics Reports Third Quarter 2020 Financial Results

  11/9/2020

  Neos Therapeutics, Inc., a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, reported financial results for the third quarter ended September 30, 2020 and provided a business update.

• Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020

  11/2/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its third quarter 2020 financial results at the opening of U.S. financial markets on Monday, November 9, 2020.

• Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference - Sep 09, 2020

  9/9/2020

  Neos Therapeutics, Inc., a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m. ET.

• Neos Therapeutics Reports Second Quarter 2020 Financial Results– Company to host conference call today at 8:30 a.m. EDT –

  8/10/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the second quarter ended June 30, 2020 and provided a business update.

• Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020

  8/3/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its second quarter 2020 financial results at the opening of U.S. financial markets on Monday, August 10, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. E

• Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference

  6/16/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020, at 4:30 p.m. ET. A live webcast of the presentation will be available on the In

• Neos Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

  5/26/2020

  Neos Therapeutics, Inc. announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020, at 9:00 a.m. ET.

• Neos Therapeutics Reports First Quarter 2020 Financial Results

  5/11/2020

  Company announces reduction in force to streamline costs and accelerate the path to profitability, particularly in light of the business impact from the COVID-19 pandemic

• Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020

  5/4/2020

  Neos Therapeutics, Inc., a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, announced that it will report its first quarter 2020 financial results at the closing of U.S. financial markets on Monday, May 11, 2020.

• Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin-- N-desethyloxybutynin is the active ingredient in NT0502, the company’s development candidate for the treatment of sialorrhea --

  4/9/2020

  Neos Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,610,507, which is directed to methods of treating sialorrhea by administering N-desethyloxybutynin, the active pharmaceutical ingredient in NT0502.

• Neos Therapeutics Statement: COVID-19 Update

  3/30/2020

  Jerry McLaughlin, President and CEO, made the following statement: We want to share the steps we are taking to ensure healthcare providers and patients continue to receive support from Neos Therapeutics and that we are doing our part to ensure our whole team, and the patients we serve, are safe during the COVID-19 global pandemic. To help slow the spread of COVID-19, most of our employees have been operating under a work from

• Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results

  3/13/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the fourth quarter and fiscal year ended December 31, 2019 and provided a business update.

• Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial and Operating Results Conference Call on March 13th, 2020

  3/6/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its fourth quarter and year-end 2019 financial results prior to the opening of U.S. financial markets on Friday, March 13, 2020.

• Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference

  2/26/2020

  Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the upcoming Cowen & Co. 40th Annual Health Care Conference on Wednesday, March 4, 2020, at 11:20 a.m. ET in Boston, MA.